bioRxivCell Biology
Repression of Hypoxia-Inducible Factor-1 Contributes to Increased Mitochondrial Reactive Oxygen Species Production in Diabetes
X. Zheng, S. Narayanan, C. Xu, S. Eliasson Angelstig, J. Grünler, A. Zhao, A. Di Toro, L. Bernardi, M. Mazzone, P. Carmeliet, M. Del Sole, G. Solaini, E. A. Forsberg, A. Zhang, K. Brismar, T. A. Schiffer, N. Rajamand Ekberg, I. R. Botusan, F. Palm, S.-B. Catrina
Abstract
BackgroundExcessive production of mitochondrial reactive oxygen species (ROS) is a central mechanism for the development of diabetes complications. Recently, hypoxia has been identified to play an additional pathogenic role in diabetes. In this study, we hypothesized that ROS overproduction was secondary to the impaired responses to hypoxia due to the inhibition of hypoxia-inducible factor-1 (HIF-1) by hyperglycemia. MethodsThe dynamic of ROS levels was analysed in the blood of healthy subjects and individuals with type 1 diabetes after exposure to hypoxia (ClinicalTrials.gov registration no. NCT02629406). The relation between HIF-1, glucose levels, ROS production and its functional consequences were analyzed in renal mIMCD-3 cells and in kidneys of mouse models of diabetes. ResultsExposure to hypoxia increased circulating ROS in subjects with diabetes, but not in subjects without diabetes. High glucose concentrations repressed HIF-1 both in hypoxic cells and in kidneys of animals with diabetes, through a HIF prolyl-hydroxylase (PHD) - dependent mechanism. The impaired HIF-1 signaling contributed to excess production of mitochondrial ROS through increased mitochondrial respiration that was mediated by Pyruvate dehydrogenase kinase 1 (PDK1) and was followed by functional consequences. The restoration of HIF-1 function attenuated ROS overproduction despite persistent hyperglycemia, and conferred protection against apoptosis and renal injury in diabetes. ConclusionsWe conclude that the repression of HIF-1 plays a central role in mitochondrial ROS overproduction in diabetes and is a potential therapeutic target for diabetic complications. These findings are highly significant and timely since the first PHD inhibitor that can activate HIF-1 has been newly approved for clinical use.
- organism: mouse
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oxidants are dispensable for HIF1α stability in hypoxia
A. Kumar, M. Vaish, … R. R. Ratan·bioRxiv·May 5, 2020
- Reconstituted high-density lipoproteins rescue diabetes-impaired endothelial cell metabolic reprograming and angiogenic responses to hypoxia
K. R. Primer, Joanne T. M. Tan, … Christina A. Bursill·Arteriosclerosis Thrombosis and Vascular BiologyPeer-reviewed·Mar 20, 2025
- Red Blood Cells Serve as a Primary Glucose Sink to Improve Glucose Tolerance at Altitude
Yolanda Martí-Mateos, Zohreh Safari, … Isha H. Jain·Cell MetabolismPeer-reviewed·Feb 19, 2026
- Hypoxia mediated regulation of mitochondrial transcription factors: Implications of hypertensive renal physiology
Bhargavi Natarajan, Vikas Arige, … Nitish R. Mahapatra·bioRxiv·Jan 28, 2020
- Therapeutic effects of Hypoxia-Inducible Factor-1α (HIF-1α) on bone formation around implants in diabetic mice
Sang‐Min Oh, Jin-Su Shin, … Jaehoon Lee·bioRxiv·Aug 15, 2018
- Human primary astrocytes increase basal fatty acid oxidation following recurrent low glucose to maintain intracellular nucleotide levels
Paul G. Weightman Potter, Julia M. Vlachaki Walker, … Craig Beall·bioRxiv·Feb 26, 2018